Asthma Trial, Recruiting NCT05734261 Sponsor: University Hospital, Montpellier Condition: Asthma
Back to Asthma

Asthma Trial, Recruiting

NCT05734261
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children aged between 6 and 16 years
  • Children whose lung function test (FEV1) result is above 60% of the expected value
  • Children who have been referred to a lung function laboratory for a specific breathing test that checks for airway sensitivity, using a substance called methacholine
  • Children who have been using inhaled corticosteroids (a type of preventer medication) but have stopped taking them for at least 3 weeks before joining
  • Children who, along with at least one parent or legal guardian, have verbally agreed to take part
  • Children who are covered by a social security or health insurance plan

Who may not be able to join:

  • Children who have used a short-acting reliever inhaler (a type of bronchodilator) in the past 6 hours, or a certain type called an anticholinergic bronchodilator in the past 12 hours
  • Children who have used a long-acting bronchodilator (one approved for use in children) in the past 36 hours
  • Children who have had a respiratory infection — such as a cold, chest infection, or similar illness — within the 3 weeks before joining
  • Children who have epilepsy and are currently being treated for it
  • Children who are already taking part in another clinical study that could affect how their lungs work
  • Children or families who are unable to give proper consent, or who are considered to be in a vulnerable situation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Stefan MATECKI, MD, Montpellier Univerty Hospital

Phone: +33 4 67 33 59 12

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
7 September 2023
Est. completion
15 February 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Change in lung impedance measurement

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov